ASIT biotech appoints Yves Désiront as new Chairman of the Board of Directors

– BELGIUM, Angleur –  ASIT biotech (BSE: ASIT, EBR: ASIT), a clinical-stage biopharmaceutical company focused on the research and development of breakthrough immunotherapy products for the treatment of allergies, today announced that during the board of directors’ meeting of January 16, 2020, Harry Welten and Jean-Paul Prieels informed the board of directors of their intention to resign as directors at the next general meeting of the company.…